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Background: Recepteur d’origine nantais (RON) is a receptor tyrosine kinase whose overexpression has been
observed in human gastric cancers. This study aimed to determine whether overexpression of the variant RONΔ160
could induce tumorigenicity of gastric cancer cells in vitro or in vivo, and whether its specific small molecule
inhibitor (Compound I) could inhibit the effect of RONΔ160.
Methods: We constructed human gastric cancer cell line MGC-803 that was stably transfected with a recombinant
plasmid expressing RONΔ160, and the effect of RONΔ160 overexpression and macrophage-stimulating protein
(MSP) activation on proliferation, migration and invasion abilities of MGC-803 cells were evaluated. Tumor-bearing
mice with gastric cancer cells were used to analyze the effects of RONΔ160 overexpression and Compound I on
implanted tumor growth.
Results: In vitro, overexpression of RONΔ160 in MGC-803 cells resulted changes to their cell morphology, and promoted
cell proliferation, migration and invasion. In addition, overexpression of RONΔ160 increased the proportion of cells in the
S phase. The effect of RONΔ160 was significantly enhanced by induction of MSP inducing (p < 0.05). In vivo, RONΔ160
promoted the growth of MGC-803 cells in nude mice, including increased tumor size and weight, and lower tumor
incubation period. The Compound I inhibited the tumorigenic abilities of RONΔ160 (p <0.05).
Conclusions: The results indicate that overexpression of the variant RONΔ160 altered the phenotype and tumorigenicity
of MGC-803 cells. Its specific small molecule inhibitor could inhibit the effect of RONΔ160. Therefore, the variant RONΔ160
may become a potential therapeutic target for gastric cancer.
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Gastric cancer is one of the most common malignant
tumors, whose onset is difficult to diagnose. At the time
of definite diagnosis, most patients are at the middle or
late stage, and their response therapy and prognosis are
poor. Thus, it is especially important to identify new
molecular markers and therapeutic targets for gastric
cancer. Studies have shown that the abnormal expression
of RON, a member of the large RTK protein family, plays
an important role in the incidence and development of tu-
mors [1]. RON also plays an important role in the growth,* Correspondence: zdh19838@163.com
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unless otherwise stated.differentiation and proliferation of epithelial cells. RON is
barely or not expressed in normal epithelial tissue, while
in breast, colon, lung, thyroid, skin, bladder and pancreas
tumors it is highly expressed and is usually accompanied
by the generation of variants [2,3]. Currently, nine
types of RON variants have been identified from primary
carcinoma and cell lines, which are termed RONΔ170,
RONΔ165, RONΔ165.e11p, RONΔ160, RONE5/6in,
RONΔ155, RONΔp110, RONΔ85 and RONΔ55, respect-
ively [4-7]. These variants are generated by three main
mechanisms: alternative splicing, protein truncation and
alternative transcription of precursor RON mRNA [8].
RON is activated mainly in a ligand dependent manner.
Currently, the sole known ligand of RON is macrophage-
stimulating protein (MSP). Maturate MSP is formed byhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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through disulfide bonds. The binding of RON with the β
chain significantly increases RON’s kinase activity and
results in phosphorylation of the kinase domain [9]. RON
contains functional domains that play important roles in
ligand binding, protein maturation and bioactivity [5,10].
For example, deletion of the first immunoglobulin-plexin-
transcription (IPT) unit of the extracellular segment of β
chain produces variant RONΔ160, which is oncogenic and
mediates many signals for tumor generation [11]. However,
the effect of RONΔ160 on the incidence and development
of gastric cancer has not been reported.
In this study, we explored the impact of RONΔ160 on
the growth and invasion of MGC-803 cells by producing
a derivative of MGC-803 that stably expresses high
levels of RONΔ160. We also investigated the inhibitory
action of a small molecule inhibitor of RONΔ160. This
established the theoretical basis for exploring new thera-
peutic targets for the gastric cancer.
Materials and methods
Materials
Human gastric cancer line MGC-803 was obtained from
the State Key Laboratory for Diagnosis and Treatment
of Infectious Diseases, The First Affiliated Hospital,
Zhejiang University School of Medicine. PrimeScript™
RT reagent kit and SYBR Premix Ex Taq™ reagent kits
were purchased from Takara Biotechnology (Dalian
Co., Ltd, China). Lipofectamine™ 2000 and the cell
cycle reagent kit were purchased from Invitrogen (Life
Technologies, USA). Hygromycin B and c-Met/RON
small molecular inhibitor (Compound I) were obtained
from Calbiochem. Recombinant human MSP was pur-
chased from R&D systems. Cell counting kit 8 (CCK-8)
was purchased from Dojindo Molecular Technologies
(Rockville, USA). Antibodies against RON (β-chain)
were purchased from Santa Cruz Biotechnology (USA).
The recombinant plasmid pcDNA3.1-RONΔ160 and
blank plasmid pcDNA3.1 were obtained from Sangon
Biotech Co., Ltd (China). Female Balb/c athymic nude
mice (Nu/Nu) aged 6-weeks were obtained from the
B&K Universal Group and were kept in temperature-
controlled rooms with a 12-h alternating light-dark cycle.
Cell cultures and transfection
MGC-803 cells were cultured in RMPI-1640 medium
with 10% fetal calf serum (FCS). One day before transfec-
tion, cells were plated at a density of 60%-70% confluence.
Transfection was made in the following groups: MGC-803
cells transfected pcDNA3.1-RONΔ160 (RONΔ160 group),
MGC-803 cells transfected with blank plasmid pcDNA3.1
(empty vector control group), and non-transfected MGC-
803 cells (MGC-803 group). Transfection was conducted
in accordance with the instruction of Lipofectamine™ 2000reagent. After 24 hours, the cells were digested and di-
luted (1:10) with fresh culture media. After a further
24 hours 200 mg/L of Hygromycin B was added to select
positive clones, which were obtained after about 2 weeks.
Positive clones were expanded in culture medium with
200 mg/L Hygromycin B. Ultimately, MGC-803 cells sta-
bly expressing pcDNA3.1-RONΔ160 and blank plasmid
pcDNA3.1 were obtained after about 8 weeks.
Western blotting
Proteins from each group were separated through 8%
SDS-PAGE and then transferred to polyvinylidene difluor-
ide (PVDF) membranes. The membranes were blocked
with 5% nonfat milk for 2 h at room temperature and in-
cubated with specific antibodies overnight at 4°C. After
thorough washing, the membranes were incubated with
HRP-conjugated secondary antibody. Visualization of the
reaction was conducted with enhanced chemilumines-
cence (ECL) reagents and analyzed by VersaDoc Imaging
system (Bio-Rad).
Quantitative real-time RT-PCR
According to the manufacturer’s instructions, the PCR
reaction was carried out with the following primers:
RONΔ160 forward: 5′-CTTGGCTGAGGTCAAGGAT
GTG-3′; RONΔ160 reverse: 5′-CGATTCTGGGCCT
GGTCTATG-3′; β-actin forward: 5′-CCAACCGCGAG
AAGATGA-3′; β-actin reverse: 5′-CCAGAGGCGTAC
AGGGATAG-3′. The amplification profile comprised
precycling at 95°C for 20 s; followed by 40 cycles of
denaturation at 95°C for 15 s, annealing at 60°C for 60 s
and extension at 72°C for 40 s.
CCK-8 assay
Cells were seeded into 96-well plates at a concentration
of 2 × 103 cells/well, which were cultured in RPMI 1640
medium with 1% FCS. A RONΔ160 +MSP group of cells
was created, to which were added MSP of final concentra-
tion 2nM. After seeding for 24-168 hours, the proportion
of live cells was detected consecutively using CCK-8 re-
agent. Finally, the absorbance (OD) value was measured
with a microplate reader at wavelength of 450 nm. The
experiment was carried out in triplicate.
Transwell invasion assay
The cells were seeded at a density of 5 × 104 cells/chamber
into the Transwell upper chamber (8.0 μm size micro-
pore filtering membrane). The lower chamber was filled
with 600 μl of 10% FCS containing RPMI 1640 culture
media. After 24 h of incubation, the cells were fixed for
30 minutes with methanol. After washing with PBS, the
cells that penetrated to the lower surface of the filter were
stained with 0.1% crystal violet solution and counted
under the microscope at a magnification × 400 field.
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Cells from each group were seeded into 6-well plates at
concentration of 5 × 105 cells/well, and cultured in 1%
FCS-containing RPMI 1640 culture media. At 95% con-
fluence, the wounds were created with 200 μl micropip-
ette tip. MSP at a final concentration of 2 nM was added
into the RONΔ160 +MSP group for further stimulation.
The cells were photographed at 0 hour and 48 hours
after wounding, and the percentages of cell migration
distance in 48 hours compared with the blank scratching
distance at 0 hour were calculated.
Cell cycle assay
After digestion with trypsin, 2 × 105–1 × 106 cells were
collected, washed with PBS, fixed in pre-cooled 70%
ethanol overnight at -20°C., The ethanol was removed
after centrifugation, the cells were hydrated with PBS for
15 minutes, before 50 μl RNase A was added and the
cells incubated in a 37°C water bath for 30 minutes.
Finally, 200 μl of propidium iodide was added to cells
for 30 minutes at 4°C with light-shielding to stain the
cells. The cells were analyzed by flow cytometry. (FACScan,
Calif., USA).
In vivo tumor growth and treatment
The effect of RONΔ160 on the tumorigenic ability of
MGC-803 cells was determined by analyzing the subcuta-
neous tumor formation ability in 6-week-old BALB/c
athymic female nude mice. The backs of the nude mice
were subcutaneously planted with cells and the experi-
ment was conducted in groups as follows: CP-I group wasFigure 1 RONΔ160 is stably transfected into MGC-803 cell line and in
MGC-803 Group; Lane 2, empty vector control (control); Lane 3, RONΔ160 Gro
control. #: p <0.01. C) RONΔ160 induces a change in morphology from previosubcutaneously planted with MGC-803 cells stably trans-
fected with RONΔ160, and from the second day they were
intraperitoneally injected with the small molecule inhibi-
tor c-Met/RON (Compound I) at dosage of 100 mg/kg for
4 weeks, twice every week; the RONΔ160 group was
subcutaneously planted with MGC-803 cells stably
transfected with pcDNA3.1-RONΔ160; the MGC-803
group was subcutaneously planted with MGC-803 cells;
and control group was subcutaneously planted with
MGC-803 cells transfected with the blank plasmid
pcDNA3.1. The latter three groups were injected with
normal saline using the same protocol the same as that for
the CP-I group. The growth of subcutaneous-transplanted
tumors was observed daily. After the formation of tumors,
the tumor volume was measured every 3 days, and the in-
cubation period of the tumor was recorded, i.e. the time
from transplantation of tumor cells till the day when the
tumor reached a volume of 500 mm3. After the tumor cells
had been implanted for 40 days, the nude mice were
killed by cervical disruption, the tumors were peeled off,
and their volumes and weights were measured. All ex-
periments involving mice were carried out using the
recommendations of the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health
and were approved by the Zhejiang University Animal
Care and Use Committee.
Statistical analysis
Data were summarized as mean ± standard error ( X  S ).
Statistical significance was determined by Student’s
t test or by ANOVA, using SPSS 19.0 software. Aduces a change in morphology. A) Western blotting results: Lane 1,
up. B) Real-time RT-PCR result: β-actin mRNA was used as an internal
us flat circular shape or polygon, to a spindle.
Figure 2 RONΔ160 improves the proliferation of MGC-803 cells,
and MSP increases this effect. #: p < 0.05 (compared with the
MGC-803 Group, empty vector control and RONΔ160 Group); *:p < 0.05
(compared with the MGC-803 Group and empty vector control).
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Results
Recombinant plasmid pcDNA3.1-RONΔ160 stably
transfected into MGC-803 cells induces morphological
changes
After screening MGC-803 cells for transfection with the
recombinant plasmid pcDNA3.1-RONΔ160, western
blotting and real-time quantitative PCR verified thatFigure 3 RONΔ160 increases the invasive capacity of the MGC-803 ce
vector control (62.35 ± 3.32) and RONΔ160 group (86.48 ± 0.32), p < 0.05; co
group (103.03 ± 3.69), p < 0.05; B: *: Compared with MGC-803 group, empty
vector control and RONΔ160 group, p < 0.05.pcDNA3.1-RONΔ160 was successfully transfected into
MGC-803 cells and expressed. The RONΔ160 protein
and mRNA expression levels of the RONΔ160 group
cells were significantly higher than those of the control
and MGC-803 group (p < 0.01). The empty vector con-
trol and MGC-803 group showed almost no expression
(Figure 1A,B). The cell morphology of the RONΔ160
group changed from the previous flat circular shape or
polygon to a spindle shape (Figure 1C).
RONΔ160 improves the proliferation of MGC-803 cells
Cell proliferation was measured with the CCK-8 cell
proliferation assay. The results showed that the overex-
pression of RONΔ160 promoted significant proliferation
of MGC-803 cells in the RONΔ160 group compared with
the MGC-803 and empty vector control (p < 0.05).
Meanwhile, the cell proliferation in cells overexpressing
RONΔ160 and stimulated with MSP (the RONΔ160 +MSP
group) was significantly higher than in the RONΔ160
group, MGC-803 group and empty vector control (p < 0.05)
(Figure 2).
RONΔ160 increases the invasive capacity of MGC-803 cells
Cell invasion capacity was reflected by the number of
cells that penetrated the bottom chamber of the Trans-
well chamber through the artificial substrate Matrigel
that simulates the cell outer basement membrane. The
results showed that the invasive capacity of MGC-803ll line (×400). A: Compared with MGC-803 group (61.95 ± 2.78), empty
mpared with RONΔ160 group (86.48 ± 0.32) and RONΔ160 + MSP
vector control, p < 0.05; #: Compared with MGC-803 group, empty
Figure 4 RONΔ160 increases the motility of MGC-803 cells (×100). Compared with MGC-803 group, empty vector control and RONΔ160
group, p < 0.05; Compared with MGC-803 group, empty vector control and RONΔ160 +MSP group, p < 0.05; Compared with MGC-803 group and
empty vector control, p > 0.05.
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cantly higher than that of MGC-803 group (61.95 ± 2.78)
and the empty vector control (62.35 ± 3.32) (p < 0.05).
Meanwhile, the cell invasive capacity of the RONΔ160 +
MSP group (103.03 ± 3.69) was significantly higher than
the RONΔ160 group (p < 0.05) (Figure 3A,B).
RONΔ160 promotes the motility of MGC-803 cells
The results of the wound healing assay showed that
48 hours after scratching, the migration capacity of cells
of the RONΔ160 group (50.41 ± 2.09%) was significantly
higher than that of the MGC-803 group (28.70 ± 1.21%)
and the empty vector control (26.43 ± 1.69%) (p < 0.05).
The cell migration capacity of the RONΔ160 +MSP
group was significantly enhanced compared with the
RONΔ160 (71.18 ± 2.74%) (p < 0.05) (Figure 4).
RONΔ160 regulates the cell cycle activities of MGC-803 cells
The results showed that the proportions of cells in each
phase of the cell cycle in the MGC-803 group, empty
vector control, RONΔ160 group and RONΔ160 +MSP
group were as follows: G0-G1 phase (57.63 ± 0.50%),Figure 5 RONΔ160 results in an arrest in the S phase of the cell cycle
and empty vector control); #: p < 0.05 (compared with the MGC-803 Group(56.65 ± 0.22%), (50.78 ± 0.59%), and (32.91 ± 0.66%); S
phase (34.77 ± 0.61%), (35.67 ± 0.78%), (40.33 ± 0.25%),
and (55.22 ± 0.59%); and G2-M phase (7.61 ± 0.73%),
(8.69 ± 0.80%), (8.90 ± 0.35%), and (11.72 ± 0.30%). Com-
pared with the MGC-803 group and the empty vector con-
trol, the proportions of S phase cells of RONΔ160 group
and RONΔ160 +MSP group were larger, the proportions
of cells in G0-G1 phase were relatively smaller, and the
proportions of cells in G2-M phase were not significantly
different. There were significantly more cells in S and G0-
G1 phases in the RONΔ160 +MSP group (p < 0.05). The
proportions of cells in each phase between the MGC-803
group and the empty vector control were not significantly
different (p > 0.05). The above results showed that, in terms
of the cell cycle, overexpression of RONΔ160 promoted
proliferation of MGC-803 cells (Figure 5).
Overexpression of RONΔ160 promotes tumor growth
in vivo and its specific small molecule inhibitor can
inhibit tumor growth
We further explored the influence of RONΔ160 on
tumor growth of MGC-803 cells in tumor-bearing nudein MGC-803 cells. *: p < 0.05 (compared with the MGC-803 Group
, empty vector control and RONΔ160 Group).
Table 1 The effects of RONΔ160 and c-Met/RON small cellular inhibitor on MGC-803 cells tumor-bearing nude mice
RONΔ160 Group* CP-I Group# MGC-803 Group Empty vector control
Tumor volume (mm3) 2703.79 ± 92.66 1743.77 ± 119.75 1176.36 ± 149.13 1273.17 ± 316.23
Tumor weight (g) 1.93 ± 0.11 1.21 ± 0.33 0.89 ± 0.29 0.91 ± 0.41
Tumor incubation period (days) 12 ± 1 14.5 ± 1.5 20 ± 1.5 19.7 ± 2.52
*: p < 0.05 (compared with MGC-803 Group, empty vector control); #: p < 0.05 (compared with RONΔ160 Group).
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803 group and empty vector control, the tumorigenic
ability of cells of the RONΔ160 group was significantly
enhanced in vivo by promoting tumor growth, shorten-
ing the incubation period of tumor formation and in-
creasing the volume and weight of the tumors. In
contrast, compared with the RONΔ160 group, the CP-I
group injected with small molecule inhibitor c-Met/
RON (Compound I) showed the inhibition of the
tumorigenic superiority conferred by RONΔ160 in vivo
(p < 0.05) (Table 1, Figure 6).
Discussion
RON is a receptor with unique tyrosine kinase activity
and is a member of the proto-oncogene c-Met family.
RON may be activated by ligand-dependent or non
ligand-dependent methods. Currently, MSP, which is
synthesized by liver cells, is the only known specific lig-
and of RON. In our previous study, we showed that the
expression ratio of RON in gastric cancer tissues was
56.1%, and the corresponding expression ratio in adja-
cent tissues was 25.6%, whereas there is no or little ex-
pression in the normal gastric mucosa. The expression
level of RON is directly related to tumor invasion, lymph
node metastasis and pathological (TNM) stages, which
implies that RON plays an important role in tumorigen-
esis and development of gastric cancer [12]. Similarly,
Song et al. found that the expression of RON in gastric
cancer and lymph node metastasis tissue is higher than
that in normal gastric mucosa and lymph node tissue
without metastasis [13]. The study results of CatenacciFigure 6 In vivo effects of RONΔ160 and its specific inhibitor Compou
Group and empty vector control); #: p < 0.05 (compared with the RONΔ1
the nude mice were killed by cervical dislocation, and the tumors were peet al. showed that RON is overexpressed in 74% of can-
cer specimens from the gastroesophageal junction; thus,
they demonstrated that RON was an important prognos-
tic factor and a potential biological therapeutic target
[14]. Hence, RON plays an important role in the patho-
genesis of gastric cancer.
Generally speaking, overexpression of RON is accom-
panied by the generation of variants. Most of the vari-
ants can promote the formation of tumors and increase
invasion capacity. Studies have shown that the gener-
ation of variants plays an important role in maintaining
diversified functions of proteins [15]. Some of the RON
variants have antagonistic activity to wild-type RON.
Other variants, for example RONΔ170, which lacks 46
amino acids encoded by the 19th exon in the kinase
domain, is unable to transmit a signal and inhibit forma-
tion of tumor [16]. However, most RON variants activate
various cell signaling cascades through different sub-
strate specificities and phosphorylation modes, thereby
altering cell migration, invasion and proliferation, and
promoting the formation of an invasive phenotype and
tumor development, e.g. RONΔ160 [2,17]. RONΔ160 is
formed by a lack of exons 5 and 6, which encode 109
amino acids of the first IPT unit in the extracellular do-
main of the RON β chain. RONΔ160 is constitutively ac-
tivated by phosphorylation of residual groups of tyrosine
and can withstand anti-RON antibody-mediated recep-
tor internalization, which contributes to its maintenance
of the in-cell signaling cascades and promotes the
in vitro transformation of cells and the in vivo growth of
tumors [5,11].nd I on MGC-803 cells. A), *: p < 0.05 (compared with the MGC-803
60 Group). B), after implanting tumor cells subcutaneously for 40 days,
eled off and photographed.
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and its variant RONΔ160 in the human gastric cancer
cell line MGC-803, which makes it a good in vitro
carrier for studying the effect of RON on the bioactivity
of gastric cancer cells. Through stable-transfection of
MGC-803 cells with a variant RONΔ160 expressing
plasmid, the overexpression of RONΔ160 in gastric cancer
cells was successfully simulated. The observed change in
the shape of RONΔ160 overexpressing MGC-803 cells
from the previous flat circular shape or polygon to a spin-
dle is similar to the result of Xu et al. [18], which con-
firmed that overexpression of RON changes the original
shape of MDCK cells. The change of cell shape is likely
related to RONΔ160-mediated epithelial-mesenchymal
transition (EMT), i.e. losing the normal characteristics of
epithelial cells and manifesting a malignant transformed
mesenchymal cell phenotype [6]. In addition, the cell
proliferation, migration and invasion assays showed that
overexpression of RONΔ160 significantly promotes pro-
liferation, migration and invasion of MGC-803 cells
in vitro. These effects were significantly enhanced after
stimulation with RON’s sole specific ligand MSP, which
further confirmed the tumorigenicity of variant RONΔ160.
Meanwhile, cell cycle analysis also showed that RONΔ160
expressing cells are significantly more likely to be in the S
phase and the proportion in the G0-G1 phase was relatively
decreased, which further verified that the overexpression of
RONΔ160 promotes proliferation of MGC-803 cells. To
further explore the biological function of RONΔ160, the
nude mice tumor-bearing animal model was used. The re-
sults showed that the in vivo tumorigenic ability of MGC-
803 cells stably transfected with the variant RONΔ160
plasmid is significantly increased via promotion of tumor
growth, shortening of the incubation period of tumor
formation and by increasing the volume and weight of the
tumors. Addition of the small molecule inhibitor Com-
pound I inhibited the tumorigenic effects of RONΔ160
and slowed the growth of the transplanted tumors in the
nude mice. The RON/c-Met dual kinase inhibitor Com-
pound I specifically interrupted the signal transduction
pathways that are mediated by the hepatocyte growth fac-
tor and macrophage-stimulating protein, and reduces cell
migration in a dosage-dependent way, both in vitro and
in vivo [19]. The in vivo experiment conducted by Yao
et al. showed that a RON monoclonal antibody could in-
hibit the activity of RONΔ160, which inhibits the growth
of colon cancer cells and has a synergistic antitumor effect
with cytotoxic drugs [20]. The above in vivo results fur-
ther confirmed the tumorigenicity of RONΔ160 and indi-
cate the possibility of using RON as the new therapeutic
target for gastric cancer.
In summary, this is the first report of the influence of
variant RONΔ160 on the biological behavior of gastric
cancer. The overexpression of variant RONΔ160 promotesthe proliferation, migration and invasive capacity of a hu-
man gastric cancer cell line and its specific small molecule
inhibitor can reverse the effects, possibly representing a
novel route of targeted therapy. Therefore, our results pro-
vide a theoretical basis for the identifying new therapeutic
targets for gastric cancer and the development of corre-
sponding targeted drugs.
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